Intelligent Pathological Diagnosis of Gestational Trophoblastic Diseases via Visual-Language Deep Learning Model

Pathologists examine tissue sections across multiple magnifications and slides, integrating morphological information to establish a diagnosis. In contrast, most pathology foundation models encode thousands of image patches from a single representative ("best") slide and aggregate their features, limiting multiscale and patient-level contextual integration. Here we introduce WILSON, a vision-language foundation model that represents whole-slide images and multi-slide cases through multi-magnification composites. Trained on approximately 189,000 slides spanning 42 organs and 838 diagnostic entities, WILSON enables patient-level analysis, multimodal retrieval and diagnostic text generation. Without task-specific training, WILSON outperformed a dedicated case-level model (macro-F1, 0.52 versus 0.38) and matched substantially larger slide-level models while requiring 400-1,350 times fewer computational operations. End-to-end fine-tuning improved breast cancer subtyping and stromal lymphocyte grading. WILSON also surpassed PRISM in image-text retrieval (recall@1, 75.6% versus 58.1%) and generated diagnostic descriptions that received higher ratings from five board-certified pathologists than competing models. These findings demonstrate that compact, multiscale representations can support computationally efficient, clinically grounded pathology foundation models.

Vision-language models used for decisions in histopathology rarely return calibrated probabilities over the candidates a user cares about. Decision-native models write a question and a candidate set chosen at run time into the input and return a normalised distribution from a small decision head in one forward pass. We build PathJev-P, a decision-native model for histopathology: MedGemma-1.5-4B with LoRA adapters and a decision head, trained on 40,000 patch states from three public collections whose expert labels are turned into typed questions with organ-specific candidate sets and a "none of these" option. In a comparison over 3 seeds with an analysis plan fixed before testing, on test sets without documented overlap with the training data of the backbone, PathJev-P is more accurate than a generative model trained with the same backbone, data and selection rule, the zero-shot pathology model CONCH and a general medical decision model (balanced accuracy 0.541 against 0.492, 0.345 and 0.213); its advantage over the generative model comes from two organs absent from training. The calibration advantage depends on how the generative model's probabilities are read out. With the summed candidate log-likelihood used in previous work, PathJev-P has the lower calibration error (ECE 0.204 against 0.279); with a length-normalised read-out of the same generative model, examined post hoc, the two have similar mean calibration error (0.201) and the generative model is better calibrated on the unseen organs, where PathJev-P remains over-confident. A supervised linear probe on a pathology foundation model is better calibrated in every setting. In a qualitative whole-slide demonstration, PathJev-P labels unsupervised tissue clusters with abstention and separates carcinoma from other tissue while running the model on a fraction of the tiles.

Gastric cancer remains a major cause of cancer mortality, yet its histological and molecular heterogeneity complicates diagnosis and risk stratification. General-purpose pathology foundation models (PFMs) often plateau on fine-grained endpoints central to gastric cancer care, and few have undergone rigorous prospective validation or clinical reader studies. We present GRACE, a Gastric-specific foundation model for Real-world Assessment and Clinical dEcision support. GRACE was developed from multicenter gastric pathology datasets totaling 48,364 primarily HE-stained whole-slide images from 37,493 patients. When evaluated on 28 clinically relevant tasks, GRACE consistently outperformed representative pancancer PFMs, achieving a macro-AUC of 0.9188, with strong performance for precancerous lesion diagnosis (macro-AUC 0.9322), tumor histopathological assessment (macro-AUC 0.9119), molecular profiling (macro-AUC 0.8682), and prognostic prediction. Beyond benchmarking, GRACE's translational value was substantiated through a rigorous evidence chain. Under safety-gated criteria requiring 100% NPV for rule-out and 100% PPV for rule-in, GRACE streamlined review for up to 69.6% of malignancy-diagnosis cases and triaged 46.8% of MMR-IHC follow-up requests. This translational feasibility was further strengthened by a randomized crossover reader study of pathologist-AI collaboration. With GRACE assistance, diagnostic accuracy improved from 82.0% to 89.9%, yielding nearly twofold higher adjusted odds of a correct diagnosis (OR 1.987) alongside concurrent gains in sensitivity and specificity. AI assistance also reduced diagnostic time by 14.9%, elevated diagnostic confidence by 9.0%, and markedly improved inter-rater agreement. When calibrated to maintain non-inferior performance to senior pathologists, the AI-assisted workflow could triage 60.7% of atrophy and 82.7% of intestinal metaplasia cases.